Lisinopril And Hydrochlorothiazide
NDC Package 53808-0451-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Lisinopril And Hydrochlorothiazide is tablets are indicated for the treatment of hypertension.These fixed-dose combinations are not indicated for initial therapy (seeDOSAGE AND ADMINISTRATION).In using lisinopril and hydrochlorothiazide tablets, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. Marketed by State Of Florida Doh Central Pharmacy, this product is identified by NDC 53808-0451 and is authorized under FDA application ANDA077321.

Identification & Billing

NDC Package Code
53808-0451-1
Package Description
30 TABLET in 1 BLISTER PACK
Product Code
53808-0451
11-Digit Billing Format
53808045101

Clinical Specifications

Proprietary Name
Lisinopril And Hydrochlorothiazide
Dosage Form
-
Usage Information
Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension.These fixed-dose combinations are not indicated for initial therapy (seeDOSAGE AND ADMINISTRATION).In using lisinopril and hydrochlorothiazide tablets, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (SeeWARNINGS.)In considering use of lisinopril and hydrochlorothiazide tablets, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in black than in nonblack patients. (SeeWARNINGS,Lisinopril.)

Regulatory & Marketing

Labeler Name
State Of Florida Doh Central Pharmacy
FDA Application #
ANDA077321
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-01-2009
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 53808-0451-1 identifies a specific commercial package of 30 tablet in 1 blister pack of Lisinopril And Hydrochlorothiazide, labeled by State Of Florida Doh Central Pharmacy. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by State Of Florida Doh Central Pharmacy on July 01, 2009. The current certification is valid through December 31, 2017.

How is this State Of Florida Doh Central Pharmacy product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 53808045101. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
53808-0451-1
11-Digit CMS (5-4-2)
53808-0451-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.